Activity
| Date | Panel | Item | Activity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
16 actions
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.50 | CYP2C9 | David Metz edited their review of gene: CYP2C9: Changed phenotypes: Phenytoin metabolism - increased risk toxicities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.50 | CYP2C9 |
David Metz changed review comment from: 25099164 Reduced phenytoin metabolism, increased risk phenytoin-induced SJS/TEN If CYP2C9 IM or PM and phenytoin naive, avoid phenytoin.; to: 25099164 If CYP2C9 IM, consider 25% reduction starting dose (moderate recommendation). If CYP2C9 PM, consider 50% reduction starting dose phenytoin (strong recommendation). |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.50 | CYP2C9 |
David Metz edited their review of gene: CYP2C9: Added comment: 25099164 Reduced phenytoin metabolism, increased risk phenytoin-induced SJS/TEN If CYP2C9 IM or PM and phenytoin naive, avoid phenytoin.; Changed publications: 18406467, 25099164; Changed phenotypes: Increased risk phenytoin-induced SJS/TEN |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | CYP2C9 |
David Metz changed review comment from: (32189324) Note poor metabolizer status has increased exposure (and possible sensitivity) to certain NSAIDs. "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen, and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity." Probably not sufficient evidence to test for CYP2C9 alone, however if information available may be worth noting.; to: (32189324) Note poor metabolizer status has increased exposure (and possible sensitivity) to certain NSAIDs. "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen, and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity." Probably not sufficient evidence to test for CYP2C9 alone, however if information available may be worth noting. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | CYP2C9 |
David Metz commented on gene: CYP2C9: (32189324) Note poor metabolizer status has increased exposure (and possible sensitivity) to certain NSAIDs. "Alternative therapies not primarily metabolized by CYP2C9 include aspirin, ketorolac, naproxen, and sulindac. Selection of therapy will depend on individual patient treatment goals and risks for toxicity." Probably not sufficient evidence to test for CYP2C9 alone, however if information available may be worth noting. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.33 | CYP2C9 | David Metz reviewed gene: CYP2C9: Rating: ; Mode of pathogenicity: None; Publications: 18406467; Phenotypes: ; Mode of inheritance: None | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.31 | CYP2C9 | Zornitza Stark Publications for gene: CYP2C9 were set to 25099164 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.30 | CYP2C9 | Zornitza Stark edited their review of gene: CYP2C9: Changed publications: 25099164, 21900891, 28198005 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.29 | CYP2C9 | Zornitza Stark Publications for gene: CYP2C9 were set to | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.28 | CYP2C9 | Zornitza Stark edited their review of gene: CYP2C9: Changed publications: 25099164 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.19 | CYP2C9 | Zornitza Stark edited their review of gene: CYP2C9: Added comment: Activity levels of CYP2C9 are at 1-2% of adult values in the fetus during the first trimester. These levels gradually increase to 30% of adult values at term. There is a high variability in these levels during the first 5 months of life, with levels eventually approaching adult values somewhere between 5 months and 2 years of age.; Changed phenotypes: Warfarin sensitivity, MIM# 122700, Phenytoin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.8 | CYP2C9 | Zornitza Stark Marked gene: CYP2C9 as ready | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.8 | CYP2C9 | Zornitza Stark Gene: cyp2c9 has been classified as Green List (High Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.8 | CYP2C9 | Zornitza Stark Classified gene: CYP2C9 as Green List (high evidence) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.8 | CYP2C9 | Zornitza Stark Gene: cyp2c9 has been classified as Green List (High Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacogenomics_Paediatric v0.7 | CYP2C9 |
Zornitza Stark gene: CYP2C9 was added gene: CYP2C9 was added to Pharmacogenomics_Paediatric. Sources: Expert list Mode of inheritance for gene: CYP2C9 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted Phenotypes for gene: CYP2C9 were set to Warfarin sensitivity, MIM# 122700; Phenytoin Review for gene: CYP2C9 was set to GREEN Added comment: Sources: Expert list |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||